{"id":18974,"date":"2022-01-18T15:15:57","date_gmt":"2022-01-18T14:15:57","guid":{"rendered":"https:\/\/www.idisantiago.es\/grupo-de-investigacion\/c028-reumatologia-experimental-y-observacional\/"},"modified":"2026-02-25T08:33:00","modified_gmt":"2026-02-25T07:33:00","slug":"c028-reumatologia-experimental-y-observacional","status":"publish","type":"project","link":"https:\/\/www.idisantiago.es\/en\/grupo-de-investigacion\/c028-reumatologia-experimental-y-observacional\/","title":{"rendered":"C028 &#8211; Experimental and Observational Rheumatology"},"content":{"rendered":"<p>[et_pb_section fb_built=&#8221;1&#8243; _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; custom_padding=&#8221;0px||||false|false&#8221; da_disable_devices=&#8221;off|off|off&#8221; global_colors_info=&#8221;{}&#8221; da_is_popup=&#8221;off&#8221; da_exit_intent=&#8221;off&#8221; da_has_close=&#8221;on&#8221; da_alt_close=&#8221;off&#8221; da_dark_close=&#8221;off&#8221; da_not_modal=&#8221;on&#8221; da_is_singular=&#8221;off&#8221; da_with_loader=&#8221;off&#8221; da_has_shadow=&#8221;on&#8221;][et_pb_row _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; width=&#8221;100%&#8221; custom_padding=&#8221;0px||||false|false&#8221; locked=&#8221;off&#8221; collapsed=&#8221;on&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text _builder_version=&#8221;4.19.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p>\u00c1REA: <a href=\"https:\/\/www.idisantiago.es\/en\/research-areas-2\/a007-infectology-inflammation-and-vaccines\/\">INFECTOLOGY, INFLAMMATION AND VACCINES<\/a><\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=&#8221;2_3,1_3&#8243; _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; width=&#8221;100%&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;2_3&#8243; _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_image src=&#8221;https:\/\/www.idisantiago.es\/wp-content\/uploads\/2022\/02\/Reumatologia-Experimental-y-Observacional-scaled.jpg&#8221; title_text=&#8221;cof&#8221; _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_image][et_pb_toggle title=&#8221;Objectives and lines of research&#8221; admin_label=&#8221;Objetivos y l\u00edneas de investigaci\u00f3n&#8221; _builder_version=&#8221;4.19.4&#8243; _module_preset=&#8221;default&#8221; body_font=&#8221;|300|||||||&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h3>Objectives<\/h3>\n<p>The objective of our group is to improve the clinical management of patients with rheumatoid arthritis using observational and experimental studies with genetic, cell and molecular biology tools.<br \/>Specifically, on the one hand, the aim is to find biomarkers of poor prognosis in patients with arthritis of recent onset and to detect severe manifestations. On the other hand, it is intended to identify new therapeutic targets for the development of therapies that manage to control the disease in patients who do not respond to current treatments.<\/p>\n<h3>Lines of research<\/h3>\n<p>The group is currently working on three lines of research in rheumatoid arthritis:<\/p>\n<p>1) Search for classification and prognostic biomarkers at the first visit of patients with inflammatory arthritis.<br \/>2) Search for predictive biomarkers of a rare and severe manifestation of rheumatoid arthritis, interstitial lung disease.<br \/>3) Search for new therapeutic targets in rheumatoid arthritis by studying the WNT5A signaling pathway and TRIB pseudokinases.<\/p>\n<p>&nbsp;<\/p>\n<p>[\/et_pb_toggle][et_pb_toggle title=&#8221;Research team&#8221; admin_label=&#8221;Equipo investigador&#8221; _builder_version=&#8221;4.21.0&#8243; _module_preset=&#8221;default&#8221; body_font=&#8221;|300|||||||&#8221; hover_enabled=&#8221;0&#8243; global_colors_info=&#8221;{}&#8221; sticky_enabled=&#8221;0&#8243;]<\/p>\n<table style=\"width: 100%; border-collapse: collapse; border-style: hidden;\" border=\"0\">\n<tbody>\n<tr>\n<td style=\"width: 50%;\"><strong>Leader<\/strong><br \/>Gonz\u00e1lez Mart\u00ednez-Pedrayo, Antonio<\/p>\n<p>&nbsp;<\/p>\n<p><strong>Members<\/strong><br \/>Campos Franco, Joaqu\u00edn<br \/>Conde Muro, Carmen<br \/>D\u00edaz Garel, Juan Jos\u00e9<br \/>Kaczmarczyk, Bartosz<br \/>Peinado Mu\u00f1oz, Marina<\/p>\n<\/td>\n<td style=\"width: 50%;\">\u00a0<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>[\/et_pb_toggle][et_pb_toggle title=&#8221;Projects&#8221; admin_label=&#8221;Proyectos (cambiar s\u00f3 codigo IDIS)&#8221; _builder_version=&#8221;4.19.4&#8243; _module_preset=&#8221;default&#8221; body_font=&#8221;|300|||||||&#8221; locked=&#8221;off&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n\n<p>[\/et_pb_toggle][et_pb_toggle title=&#8221;Publications&#8221; admin_label=&#8221;Publicaciones&#8221; _builder_version=&#8221;4.19.4&#8243; _module_preset=&#8221;default&#8221; body_font=&#8221;|300|||||||&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<ul>\n<li>Regueiro C, Casares-Marfil D, Lundberg K, Knevel R, Acosta-Herrera M, Rodriguez-Rodriguez L, Lopez-Mejias R, Perez-Pampin E, Triguero-Martinez A, Nu\u00f1o L, Ferraz-Amaro I, Rodriguez-Carrio J, Lopez-Pedrera R, Robustillo-Villarino M, Casta\u00f1eda S, Remuzgo-Martinez S, Alperi M, Alegre-Sancho JJ, Balsa A, Gonzalez-Alvaro I, Mera A, Fernandez-Gutierrez B, Gonzalez-Gay MA, Trouw L, Gr\u00f6nwall C, Padyukov L, Martin J, Gonzalez A. <strong>HLA-B*08 identified as the most associated MHC locus for anti-carbamylated protein antibody-positive\/anti-CCP-negative rheumatoid arthritis<\/strong>. <em>Arthritis Rheumatol<\/em>. 2021; 73(6): 963-969. Dec 31. <span style=\"color: #808000;\"><strong><a style=\"color: #808000;\" href=\"https:\/\/doi.org\/10.1002\/art.41630\">doi: 10.1002\/art.41630<\/a><\/strong><\/span>. PMID: 33381897<\/li>\n<li>Regueiro C, Nu\u00f1o L, Triguero-Martinez A, Ortiz AM, Villalba A, B\u00f3veda MD, Mart\u00ednez-Feito A, Conde C, Balsa A, Gonz\u00e1lez-Alvaro I, Gonzalez A.<strong> Increased disease activity in early arthritis patients with anti-carbamylated protein antibodies<\/strong>.<em>\u00a0Sci Rep<\/em>. 2021 May 11;11(1):9945. <strong><span style=\"color: #808000;\"><a style=\"color: #808000;\" href=\"https:\/\/doi.org\/10.1038\/s41598-021-89502-y\">doi: 10.1038\/s41598-021-89502-y<\/a><\/span><\/strong>. PMID: 33976334<\/li>\n<li>Rodriguez-Trillo A, Mosquera N, Pena C, Rivas-Tobio F, Mera-Varela A, Gonzalez A, Conde C. <strong>Non-canonical WNT5A signaling through RYK contributes to aggressive phenotype of the rheumatoid fibroblast-like synoviocytes<\/strong>. <em>Front Immunol<\/em> 2020. 11:555245. <strong><span style=\"color: #808000;\"><a style=\"color: #808000;\" href=\"https:\/\/doi.org\/10.3389\/fimmu.2020.555245\">doi: 10.3389\/fimmu.2020.555245 \u00a0<\/a><\/span><\/strong><\/li>\n<li><span style=\"color: #000000;\">Regueiro C, Rodriguez-Rodriguez L, Lopez-Mejias R, Nu\u00f1o L, Triguero-Martinez A, Perez-Pampin E, Corrales A, Villalba A, Lopez-Golan Y, Abasolo L, Remuzgo-Mart\u00ednez S, Ortiz AM, Herranz E, Mart\u00ednez-Feito A, Conde C, Mera-Varela A, Balsa A, Gonzalez-Alvaro I, \u00c1ngel Gonz\u00e1lez-Gay M, Fernandez-Gutierrez B, Gonzalez A <\/span><strong>A predominant involvement of the triple seropositive patients and others with rheumatoid factor in the association of smoking with rheumatoid arthritis<\/strong>. <em>Sci Rep.<\/em> 2020;10:3355. <span style=\"color: #808000;\"><strong><a style=\"color: #808000;\" href=\"https:\/\/doi.org\/10.1038\/s41598-020-60305-x\">doi:10.1038\/s41598-020-60305-x<\/a><\/strong><\/span>. PMID: 32098994.<\/li>\n<li>Mosquera N, Rodriguez-Trillo A, Blanco FJ, Mera-Varela A, Gonzalez A, Conde C. <strong>All-Trans Retinoic Acid Inhibits Migration and Invasiveness of Rheumatoid Fibroblast-Like Synoviocytes<\/strong>.<em> J Pharmacol Exp Ther<\/em>. 2020 Feb;372(2):185-192. <strong><span style=\"color: #808000;\"><a style=\"color: #808000;\" href=\"https:\/\/doi.org\/10.1124\/jpet.119.261370\">doi: 10.1124\/jpet.119.261370<\/a><\/span><\/strong>. Epub 2019 Dec 4. PMID: 31801802<\/li>\n<li>Rodriguez-Mart\u00ednez L, Bang H, Regueiro C, Nu\u00f1o L, Triguero-Martinez A, Peiteado D, Ortiz AM, Villalba A, Martinez-Feito A, Balsa A, Gonzalez-Alvaro I, Gonzalez A. <strong>Improved classification of rheumatoid arthritis with a score including anti-acetylated ornithine antibodies<\/strong>. <em>Sci Rep.<\/em> 2020 Nov 6;10(1):19263. <span style=\"color: #808000;\"><strong><a style=\"color: #808000;\" href=\"https:\/\/doi.org\/10.1038\/s41598-020-73919-y\">doi: 10.1038\/s41598-020-73919-y<\/a><\/strong><\/span>. PMID: 33159095<\/li>\n<li>Regueiro C, Rodriguez-Rodriguez L, Triguero-Martinez A, Nu\u00f1o L, Casta\u00f1o-Nu\u00f1ez AL, Villalva A, Perez-Pampin E, Lopez-Golan Y, Abasolo L, Ortiz AM, Herranz E, Pascual-Salcedo D, Mart\u00ednez-Feito A, Boveda MD, Gomez-Reino JJ, Mart\u00edn J, Gonzalez-Escribano MF, Fernandez-Gutierrez B, Balsa A, Gonzalez-Alvaro I, Gonzalez A. <strong>Specific Association of HLA-DRB1*03 With Anti-Carbamylated Protein Antibodies in Patients With Rheumatoid Arthritis<\/strong>. <em>Arthritis Rheumatol.<\/em> 2019 Mar;71(3):331-339. <span style=\"color: #808000;\"><strong><a style=\"color: #808000;\" href=\"https:\/\/doi.org\/10.1002\/art.40738\">doi: 10.1002\/art.40738<\/a><\/strong><\/span>.<\/li>\n<li>Regueiro C, Rodr\u00edguez-Mart\u00ednez L, Nu\u00f1o L, Ortiz AM, illalba A, Pascual-Salcedo D, Mart\u00ednez-Feito A, Gonz\u00e1lez-Alvaro I, Balsa A, Gonzalez A.<strong> Improved RA classification among early arthritis patients with the concordant pesence of three RA autoantibodies: analysis in two early arthritis clinics<\/strong>.<em> Arthritis Res Ther.<\/em> 2019 Dec 11;21(1):280. <span style=\"color: #808000;\"><strong><a style=\"color: #808000;\" href=\"https:\/\/doi.org\/10.1186\/s13075-019-2079-4\">doi: 10.1186\/s13075-019-2079-4<\/a><\/strong><\/span>.PMID: 31829260<\/li>\n<\/ul>\n<p>[\/et_pb_toggle][et_pb_toggle title=&#8221;Web del grupo&#8221; disabled_on=&#8221;on|on|on&#8221; admin_label=&#8221;Web del grupo&#8221; _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; body_font=&#8221;|300|||||||&#8221; disabled=&#8221;on&#8221; global_colors_info=&#8221;{}&#8221;]https:\/\/[\/et_pb_toggle][\/et_pb_column][et_pb_column type=&#8221;1_3&#8243; _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text admin_label=&#8221;Investigador\/a l\u00edder&#8221; _builder_version=&#8221;4.19.4&#8243; _module_preset=&#8221;default&#8221; text_text_color=&#8221;#FFFFFF&#8221; header_text_color=&#8221;#FFFFFF&#8221; header_2_text_align=&#8221;left&#8221; header_2_text_color=&#8221;#FFFFFF&#8221; background_color=&#8221;#10294c&#8221; custom_margin=&#8221;0px||||false|false&#8221; custom_padding=&#8221;6px||0px|6px|false|false&#8221; locked=&#8221;off&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h2>Lead researcher<\/h2>\n<p>[\/et_pb_text][et_pb_text admin_label=&#8221;WP Team (cambiar s\u00f3 a ID pola do l\u00edder de equipo)&#8221; _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; locked=&#8221;on&#8221; global_colors_info=&#8221;{}&#8221;]<div class=\"sp-wp-team-pro-wrapper wp-team-pro-preloader\" >\n\n<div id=\"sptp-11033\" class=\"sp-team-pro sptp-section sptp-new_page pagination_normal sptp-even\" >\n\n\t<div class=\"sp-team-pro-page-loading-image\"><\/div>\n\t<div class=\"sptp-grid\">\n\t\t<div class=\"sptp-row  \">\n\t\t\t\t\t<div class=\"sp-team-pro-item sptp-col-lg-1 sptp-col-md-1 sptp-col-sm-1 sptp-col-xs-1\"\n\t\t\t data-member=\"18798\">\n\t\t\t\t<div class=\"sptp-member  border-bg-around-member sptp-square\">\n\t<a class=\"sptp-member-avatar \"  href=https:\/\/www.idisantiago.es\/en\/team\/antonio-gonzalez-martinez-pedrayo\/ target=_blank >\n\t<div class=\"sptp-member-avatar-img-area\" data-id=\"18798\">\n\t\t<div class=\"sptp-member-avatar-img sptp-square sptp-icon-on-image none \">\n\t\t\t<div class=\"sptp-overflow-h\">\n\t\t\t\t\t\t\t\t\t<div class=\"sptp-icon text-center\">\n\t\t\t\t\t<i class=\"fa fa-plus\"><\/i>\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<img loading=\"lazy\" decoding=\"async\" class=\"sptp_default_img\" srcset=\"https:\/\/www.idisantiago.es\/wp-content\/uploads\/2022\/02\/Antonio-Gonzalez.jpg\" src=\"https:\/\/www.idisantiago.es\/wp-content\/uploads\/2022\/02\/Antonio-Gonzalez.jpg\" alt=\"Antonio Gonz\u00e1lez Mart\u00ednez-Pedrayo\" width=\"299\" height=\"168\">\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t<\/div>\n<\/a>\n\t<div class=\"sptp-member-name \">\n\t\t<h2>\n\t\t\t\t\tAntonio Gonz\u00e1lez Mart\u00ednez-Pedrayo\t\t\t\t<\/h2>\n\t<\/div>\n<div class=\"sptp-member-email\">\n\n<i class=\"fa fa-envelope\"><\/i>\t<a href=\"#0\"  class=\"\">\n\t\t<span>Antonio.Gonzalez.Martinez.Pedrayo@sergas.es<\/span>\n\t<\/a>\n\t<\/div>\n<div class=\"sptp-member-phone\">\n<i class=\"fa fa-phone\"><\/i>\t<a href=\"#0\"  class=\"\" >\n\t\t<span>(+34) 981 950 903<\/span>\n\t<\/a>\n\t<\/div>\n<div class=\"sptp-member-website\">\n<i class=\"fa fa-globe\"><\/i>\t<a href=\"http:\/\/orcid.org\/0000-0002-2624-0606\"  class=\"\" target=\"_blank\">\n\t\t<span>http:\/\/orcid.org\/0000-0002-2624-0606<\/span>\n\t<\/a>\n\t<\/div>\n<div class=\"sptp-read-more-button\">\n\t<a class=\"sptp-member-read-more-button\" href=\"https:\/\/www.idisantiago.es\/en\/team\/antonio-gonzalez-martinez-pedrayo\/\"> + INFO <\/a>\n<\/div>\n<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div> <!-- end row -->\n\t<\/div> <!-- end grid -->\n\t\t\t<\/div>\n<\/div>\n<br \/>\n[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>\u00c1REA: INFECTOLOGY, INFLAMMATION AND VACCINESObjectives The objective of our group is to improve the clinical management of patients with rheumatoid arthritis using observational and experimental studies with genetic, cell and [&hellip;]<\/p>\n","protected":false},"author":11,"featured_media":12058,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","inline_featured_image":false,"footnotes":""},"project_category":[844],"project_tag":[],"class_list":["post-18974","project","type-project","status-publish","has-post-thumbnail","hentry","project_category-infectologia-en"],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/www.idisantiago.es\/en\/wp-json\/wp\/v2\/project\/18974","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.idisantiago.es\/en\/wp-json\/wp\/v2\/project"}],"about":[{"href":"https:\/\/www.idisantiago.es\/en\/wp-json\/wp\/v2\/types\/project"}],"author":[{"embeddable":true,"href":"https:\/\/www.idisantiago.es\/en\/wp-json\/wp\/v2\/users\/11"}],"replies":[{"embeddable":true,"href":"https:\/\/www.idisantiago.es\/en\/wp-json\/wp\/v2\/comments?post=18974"}],"version-history":[{"count":22,"href":"https:\/\/www.idisantiago.es\/en\/wp-json\/wp\/v2\/project\/18974\/revisions"}],"predecessor-version":[{"id":45125,"href":"https:\/\/www.idisantiago.es\/en\/wp-json\/wp\/v2\/project\/18974\/revisions\/45125"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.idisantiago.es\/en\/wp-json\/wp\/v2\/media\/12058"}],"wp:attachment":[{"href":"https:\/\/www.idisantiago.es\/en\/wp-json\/wp\/v2\/media?parent=18974"}],"wp:term":[{"taxonomy":"project_category","embeddable":true,"href":"https:\/\/www.idisantiago.es\/en\/wp-json\/wp\/v2\/project_category?post=18974"},{"taxonomy":"project_tag","embeddable":true,"href":"https:\/\/www.idisantiago.es\/en\/wp-json\/wp\/v2\/project_tag?post=18974"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}